PMID- 24738123
OWN - NLM
STAT- MEDLINE
DCOM- 20150406
LR  - 20191112
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 40
IP  - 3
DP  - 2014 Mar
TI  - Survival and prognostic factors of patients with primary fallopian tube cancer 
      receiving adjuvant paclitaxel and carboplatin chemotherapy.
PG  - 806-11
AB  - AIM: To determine the survival and prognostic factors of patients with primary 
      fallopian tube cancer (PFTC) who had been treated with paclitaxel and carboplatin 
      chemotherapy. METHODS: The records of patients with PFTC who had been treated 
      between 2002 and 2010, identified through the report of Chiang Mai University 
      Hospital, were reviewed. All patients had pathological materials initially 
      reported or reviewed by a gynecologic pathologist before initiation of treatment. 
      RESULTS: Thirty patients met the inclusion criteria. Median age was 51 years. 
      Serous adenocarcinoma was observed in the majority of patients (76.7%). 
      Approximately 46% of patients were in stage I-II. The 5-year progression-free 
      survival (PFS) for all patients was 37.2%. The 5-year PFS was 75.0% for stage I, 
      51.4% for stage II and 18.5% for stage III. Median PFS of the entire cohort was 
      26.0 months with a 95% confidence interval (CI) of 18.7-33.3 months. This rate 
      was 18.5 months (95% CI, 6.7-35.6) for stage III whereas it was not reached for 
      patients of stage I-II. Serous histology and stage were noted to be significant 
      independent predictors of PFS with an adjusted hazards ratio of 7.54 (95% CI, 
      1.34-42.4) and 6.19 (95% CI, 1.59-24.08), respectively. CONCLUSION: The 5-year 
      PFS of the whole cohort was 37.2% with a median survival of 26 months. 
      International Federation of Gynecology and Obstetrics stage and histological 
      subtype were a significant independent factor for predicting PFS.
FAU - Kietpeerakool, Chumnan
AU  - Kietpeerakool C
FAU - Srisomboon, Jatupol
AU  - Srisomboon J
FAU - Phongsaranantakul, Supareuk
AU  - Phongsaranantakul S
FAU - Khunamornpong, Surapan
AU  - Khunamornpong S
FAU - Cheewakriangkrai, Chalong
AU  - Cheewakriangkrai C
FAU - Sribanditmongkol, Narisa
AU  - Sribanditmongkol N
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Carboplatin/administration & dosage/*therapeutic use
MH  - Carcinoma/diagnosis/*drug therapy/pathology/surgery
MH  - Chemotherapy, Adjuvant
MH  - Cohort Studies
MH  - Fallopian Tube Neoplasms/diagnosis/*drug therapy/pathology/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Hospitals, University
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage/*therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Thailand
EDAT- 2014/04/17 06:00
MHDA- 2015/04/07 06:00
CRDT- 2014/04/17 06:00
PHST- 2014/04/17 06:00 [entrez]
PHST- 2014/04/17 06:00 [pubmed]
PHST- 2015/04/07 06:00 [medline]
AID - 10.1111/jog.12241 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2014 Mar;40(3):806-11. doi: 10.1111/jog.12241.